Licenscape
 
     a Jouhou Koukai business

 

 
   Key Disease & Therapeutic Areas  
       
         

Home

       Sample Case Studies  
     

Provided are insights from previous research projects:

1. Hepatitis
2. Pancreatic cancer
3. Migraine
4. Insomnia
5. Erectil dysfunction (ED)


1. Hepatitis
Effective November 1, 2000 the Japanese Ministry of Health, Labor and Welfare created a special "Hepatitis Task Force". The prime objective of the joint task force is to generate policy and practical measures to counteract the growing number of HBV (1 million) and HCV (2 million) cases in Japan, and the highest in the world mortality rate of liver cancer. One of the main implications of the new policy will be the approval of new and advanced therapies still not available in Japan.


2. Pancreatic Cancer
For the past twenty years the malignant neoplasia have been the leading cause of death in Japan, and with 17,000 cases annually the pancreatic cancer is the fifth leading cause of cancer death. The classification of pancreatic tumors adopted in Japan differs from UICC system and along with comprehensive surgical approaches creates a significant market opportunities.

Read more in related report


3. Migraine
Recent simultaneous launch of two major products for treatment of migraine - Imigran (Sumatriptan succinate) Tablets 50 mg by GlaxoSmithKline KK and Zomig (Zolmitriptan) Tablets 2.5 mg by AstraZeneca KK signify the potential of the Japanese headache market. Around 8.4 million people in Japan are estimated to suffer from migraine or other forms of headache.

Read more in related report


4. Insomnia
Insomnia and its forms - similarly to all other conditions and disorders related to the mental activities, are difficult to approach and study in Japan. Cultural layers, controversies and still poorly understood patterns in the patients behavior all contribute to making the research on insomnia one of the most  complicated projects in medical and pharmaceutical market research.

Read more in Licenscape publication


5. Erectile dysfunction
Vendors estimations put the number of ED sufferers in Japan to be more than 1.1 million men in Japan, yet the actual figures of sales of the only two registered products - sildenafil (marketed under the brand of Viagra) and vardenafil (marketed under the brand of Levitra), suggest considerably lower number of patients taking the PDE-5 inhibitors.

Read more in related report



        Contact info@licenscape.com    

 

Licenscape Japan About; Contacts; Terms & Conditions; Privacy   

Copyright 2001-2012. All rights reserved worldwide. All materials on this web site are protected by copyrights.